ADP-A2M4CD8

Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
Yahoo Finance
Fri, 09/9/22 - 11:03 am
ESMO
Adaptimmune
clinical trials
ADP-A2M4CD8
ovarian cancer
head and neck cancer
urothelial cancer